Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 320
- Registration Number
- NCT04959175
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04898894
- Locations
- 🇺🇸
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Rady Children's Hospital-San Diego, San Diego, California, United States
A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 233
- Registration Number
- NCT04781959
- Locations
- 🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideProcedure: EchocardiographyDrug: Etoposide PhosphateBiological: FilgrastimProcedure: Lumbar PunctureBiological: PegfilgrastimBiological: NivolumabProcedure: Positron Emission TomographyRadiation: Radiation TherapyDrug: PrednisoloneDrug: PrednisoneBiological: RituximabBiological: Rituximab and Hyaluronidase HumanDrug: Vincristine Sulfate
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 244
- Registration Number
- NCT04759586
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-06-27
- Target Recruit Count
- 1034
- Registration Number
- NCT04687098
- Locations
- 🇪🇸
ICO Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitari Son Espases, Palma de Mallorca, Mallorca, Spain
🇪🇸Hospital Universitari Son Llatzer, Palma de Mallorca, Mallorca, Spain
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideProcedure: Magnetic Resonance ImagingDrug: MesnaBiological: PegfilgrastimProcedure: Peripheral Blood Stem Cell TransplantationOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Second-Look SurgeryDrug: Thiotepa
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT04684368
- Locations
- 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
Severe Bullous Drug Eruption and Filgrastim
- Conditions
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 42
- Registration Number
- NCT04651439
- Locations
- 🇫🇷
Département d'Anesthésie-Réanimation , Hôpital Edouard Herriot, Hospices Civils de Lyon, LYON cedex 03, France
🇫🇷Reference center for toxic bullous dermatoses and severe drug eruptions, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
🇫🇷Service de Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Haploidentical HCT for Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04558736
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Clinical Specimen Collection From Pompe Disease Patients
- Conditions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Serhat Gumrukcu, MD PhD
- Target Recruit Count
- 12
- Registration Number
- NCT04476550
- Locations
- 🇺🇸
Seraph Research Institute, Toluca Lake, California, United States
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CladribineDrug: CyclosporineDrug: CytarabineBiological: FilgrastimProcedure: Hematopoietic Cell TransplantationDrug: MitoxantroneDrug: IdarubicinDrug: Mycophenolate MofetilDrug: FludarabineDrug: Mycophenolate SodiumRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.